A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)
Status:
Terminated
Trial end date:
2019-07-05
Target enrollment:
Participant gender:
Summary
This study will examine the effect of treatment with the neoadjuvant antibody pembrolizumab
(MK-3475) on tumors of participants with renal cell cancer (RCC). The primary hypotheses are
that pembrolizumab is well tolerated in participants undergoing RCC tumor resection; and that
pembrolizumab will stimulate a 2-fold or greater increase in intratumoral lymphocytic
infiltration in at least 30% of participants with RCC.